If you purchased or acquired securities in GSK between February 5, 2020 and August 14, 2022 and would like to discuss your ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

Teva Pharmaceutical Industries Ltd. ADR-1.50% $19.99B ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

GSK PLC closed 21.63% short of its 52-week high of £18.24, which the company reached on May 16th.

(Alliance News) - GSK PLC on Saturday said the US Food & Drug Administration has approved its vaccine against five common disease-causing serogroups of Neisseria meningitidis. Read More ...

GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

GlaxoSmithKline is investing in artificial ... clients in one quarter of the time normally needed. Exscientia and GSK aim to discover novel and selective small molecules for up to 10 disease ...